Publicaties

Publicaties

Kiemeney LA et al. Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. Eur J Cancer 2006; 42: 3219-27. http://www.ncbi.nlm.nih.gov/pubmed/16934975

Kiemeney LA et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008; 40: 1307-12. http://www.ncbi.nlm.nih.gov/pubmed/18794855

Verhaegh GW et al. Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol 2008; 54: 1118-26. http://www.ncbi.nlm.nih.gov/pubmed/18262338

Wu X et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009; 41: 991-5. http://www.ncbi.nlm.nih.gov/pubmed/19648920

Kiemeney LA, Grotenhuis AJ, Vermeulen SH, Wu X. Genome-wide association studies in bladder cancer: first results and potential relevance. Curr Opin Urol. 2009;19(5):540-6. http://www.ncbi.nlm.nih.gov/pubmed/19553824

Grotenhuis AJ, Vermeulen SH, Kiemeney LA. Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response. Future Oncol. 2010;6(9):1433-60. http://www.ncbi.nlm.nih.gov/pubmed/20919828

Kiemeney LA et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010; 42: 415-9. http://www.ncbi.nlm.nih.gov/pubmed/20348956

Rothman N et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010; 42: 978-84. http://www.ncbi.nlm.nih.gov/pubmed/20972438

Rafnar T, Vermeulen SH, Sulem P, et al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet. 2011;20(21):4268-4281. http://www.ncbi.nlm.nih.gov/pubmed/21750109

Ros MM, Gago-Dominguez M, Aben KK, et al. Personal hair dye use and the risk of bladder cancer: a case-control study from The Netherlands. Cancer Causes Control. 2012;23(7):1139-1148. http://www.ncbi.nlm.nih.gov/pubmed/22581032

Dudek AM, Grotenhuis AJ, Vermeulen SH, Kiemeney LA, Verhaegh GW. Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms? Int J Mol Sci. 2013;14(6):12346-66. http://www.ncbi.nlm.nih.gov/pubmed/23752272 

Rafnar T, Sulem P, Thorleifsson G, Vermeulen SH, Helgason H, Saemundsdottir J, et al. Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Human molecular genetics. 2014;23(20):5545-57. http://www.ncbi.nlm.nih.gov/pubmed/24861552

Buffen K, Oosting M, Quintin J, Ng A, Kleinnijenhuis J, Kumar V, et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog. 2014;10(10):e1004485. http://www.ncbi.nlm.nih.gov/pubmed/25356988

Grotenhuis AJ, Dudek AM, Verhaegh GW, Witjes JA, Aben KK, van der Marel SL, Vermeulen SH, Kiemeney LA. Prognostic relevance of urinary bladder cancer susceptibility loci. PLoS One. 2014;9(2):e89164. http://www.ncbi.nlm.nih.gov/pubmed/24586564

Kiemeney LA. The global risk of bladder cancer: let's just do something about it! Eur Urol. 2014 Jul;66(1):74-5. http://www.ncbi.nlm.nih.gov/pubmed/24315432

Vermeulen SH, Hanum N, Grotenhuis AJ, Castano-Vinyals G, van der Heijden AG, Aben KK, et al. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. British journal of cancer. 2015;112(3):594-600. http://www.ncbi.nlm.nih.gov/pubmed/25429525

Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol. 2015;67(1):74-82. http://www.ncbi.nlm.nih.gov/pubmed/25043942

Grotenhuis AJ, Ebben CW, Aben KK, Witjes JA, Vrieling A, Vermeulen SH, Kiemeney LA. The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. Urol Oncol. 2015;33(2):65.e9-17. http://www.ncbi.nlm.nih.gov/pubmed/25023787

Roelofzen JH, Aben KK, Van de Kerkhof PC, Van der Valk PG, Kiemeney LA. Dermatological exposure to coal tar and bladder cancer risk: a case-control study. Urol Oncol. 2015;33(1):20.e19-22. http://www.ncbi.nlm.nih.gov/pubmed/24629496

Egbers L, Grotenhuis AJ, Aben KK, Alfred Witjes J, Kiemeney LA, Vermeulen SH. The prognostic value of family history among patients with urinary bladder cancer. Int J Cancer. 2015;136(5):1117-24. http://www.ncbi.nlm.nih.gov/pubmed/24978702

Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, Garcia-Closas M, Chatterjee N, et al. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. 2016 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/26732427

Grotenhuis AJ, Dudek AM, Verhaegh GW, Aben KK, Alfred Witjes J, Kiemeney LA, Vermeulen SH. Independent replication of published germline polymorphisms associated with urinary bladder cancer prognosis and treatment response. Bladder Cancer. 2016;2(1):77-89. http://content.iospress.com/articles/bladder-cancer/blc150027